Erythropoietin Drugs Market 2026 – Exclusive Analysis | by Top Industry Merchants as Amgen, GlaxoSmithKline, Pfizer, Johnson & Johnson, Novartis Etc

Global Erythropoietin Drugs Market – Insights 

Erythropoietin is a growth factor produced in the kidneys that stimulates the production of red blood cells. Erythropoietin drugs are used for the treatment of anemia induced from cancer, multiple myeloma and HIV associated anemia. Erythropoietin is extracted from the human body through in vitro process. Recombinant DNA technology is used for the production of erythropoietin drugs in various synthetic forms such as epoetin alfa, epoetin beta, epoetin delta, and epoetin omega.

Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/214

Global Erythropoietin Drugs Market: Drivers

Increasing incidence of anemia is expected to boost growth of the global erythropoietin drugs market over the forecast period. For instance, according to the World Health Organization, 2011, the worldwide prevalence of anemia is 800 million with Asia Pacific and Africa recording the highest number of cases. The prevalence of anemia in the U.S. is 5.6%.

Moreover, increasing development of biosimilars is also expected to boost growth of the market. Key pharmaceutical companies such as Amgen, Novartis, and Pfizer are focused on the development of biologic of erythropoietin. Some of the biologics that are under clinical development stage include NuPIAO, KRN321, ErepoXen, and JR-131.

Quick Buy – Erythropoietin Drugs Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/214

Global Erythropoietin Drugs Market: Regional Analysis 

On the basis of region, the global erythropoietin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Europe is expected to hold dominant position in the global erythropoietin market over the forecast period, owing to factors such as developed healthcare sector and favorable reimbursement policies in the region. Moreover, less stringent drug approval process compared to that in North America and increasing development of biologics is also expected to propel growth of the market in Europe.

The market in North America is driven by increasing clinical trials for erythropoietin drugs. Asia Pacific is expected to be the fastest growing market. China and India are growth engines of the market in Asia Pacific, owing to high incidence of anemia in the countries. For instance, in India, the prevalence of the disease is the highest among all the countries worldwide with 10.6% of YLD’s caused due to disability, according to the study conducted by India Spend. Moreover, according to study conducted by Stanford University, an estimated180 million people suffer from anemia in central and eastern China. Moreover, less stringent regulations and increasing production and launch of biologics of erythropoietin drugs is also expected to aid in growth of the market in Asia Pacific.

Global Erythropoietin Drugs Market: Competitive Landscape

Major players operating in the global erythropoietin drugs market include Amgen, GlaxoSmithKline, Pfizer, Johnson & Johnson, Novartis, Biocon, Ranbaxy Laboratories, and Teva Pharmaceutical ltd.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/erythropoietin-drugs-market-214

Global Erythropoietin Drugs Market: Key Developments

Key players in the market are focused on product approval and launch to expand their market share. For instance, in August 2019, GlaxoSmithKline plc (GSK) submitted Japanese New Drug Application (JNDA) to the Ministry of Health, Labour, and Welfare for its dapordustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment renal anemia.

In May 2018, Pfizer, Inc., a U.S.-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for RETACRIT, a biosimilar to Epogen and Procrit. It is the first and only FDA approved biosimilar erythropoiesis-stimulating agent.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837